Alterations in P-glycoprotein expression in mouse tissues by doxorubicin: Implications for pharmacokinetics in multiple dosing regimens

Chemico-Biological Interactions

Volumn 138, Issue 1, 2001, Pages 43-57

  Gustafson, Daniel L ^a   Long, Michael E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Doxorubicin; Multiple dosing; P glycoprotein; Pharmacokinetics

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG TISSUE LEVEL; DRUG TRANSPORT; FEMALE; IMMUNOBLOTTING; INTESTINE; KIDNEY; LIVER; NONHUMAN; ORGAN DISTRIBUTION; PROTEIN EXPRESSION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; INTESTINES; KIDNEY; LIVER; MICE; MICE, INBRED BALB C; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0035950431     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(01)00257-5     Document Type: Article

References (39)

1. Anthracyclines
2. Clinical pharmacokinetics of doxorubicin
3. Doxorubicin and doxorubicinol: Intra- and inter-individual variations of pharmacokinetic parameters
4. Adriamycin metabolism in man, evidence from urinary metabolites
5. Comparative mammalian metabolism of adriamycin and daunorubicin
6. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo
7. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833
8. Increased accumulation of doxorubicin and doxirubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
9. Does adriamycin undergo an enterohepatic circulation?
10. Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients
11. Pharmacokinetics of doxorubicin in man: Dose and schedule dependence
12. Effects of prior therapy on plasma levels of adriamycin during subsequent therapy
13. Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection
14. Development and identification of a multicompartment model for the distribution of adriamycin in the rat
15. Modulation of p-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers
16. Effect of dexamethasone on the intestinal first-pass metabolism of idinivar in rats; evidence of cytochrome P-450 A and p-glycoprotein induction
17. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?
18. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy
19. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cells
20. P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins
21. MDR expression in normal tissues: Pharmacologic implications for the clinical use of p-glycoprotein inhibitors
22. The physiological function of drug-transporting p-glycoproteins
23. Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
24. Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A
25. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
26. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein
27. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
28. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice
29. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats
30. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia
31. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
32. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
33. The role of mdr1a p-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice
34. Cyclosporin A treatment induces overexpression of p-glycoprotein in the kidney and other tissues
35. Cisplatin induces renal expression of p-glycoprotein and canalicular multispecific organic ion transporter
36. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents
37. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
38. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
39. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer